these receptors; thus, they are all subject to modulation by the antiepileptic drugs that target them. However, for most types of epilepsy, cortical, thalamic, and hippocampal circuits are thought to be the most vulnerable, meaning that modulation of other circuits by these drugs may bring about the risk of side effects without contributing any therapeutic benefit.
For these reasons, the authors of a recent paper in Nature Medicine set out to find an AMPA-type glutamate receptor modulator that could be targeted to forebrain circuits while sparing others such as cerebellar circuits that may underlie perampanel's side effects of dizziness and motor impairments (2) . To achieve this selectivity, they took advantage of the fact that AMPA receptors bind to auxiliary proteins called transmembrane AMPA receptor regulatory proteins (TARPs) (3). Although TARPs are not absolutely necessary for AMPA receptor function, they traffic the receptors to the membrane, alter the kinetics of the receptors, and increase current flow through the receptors (4). More importantly, there are several different TARPs, each with its own unique expression pattern. The class of TARPs that seems to play the major role in trafficking AMPA receptors consists of γ-2 (also known as stargazin), γ-3, γ-4, and γ-8 (5) . γ-8 is highly expressed in the hippocampus, as well as in the cerebral cortex and olfactory bulb, but not in the cerebellum. The authors reasoned that if they could identify a compound that selectively inhibited AMPA receptors that were associated with γ-8, then they could use it to block seizures without causing motor impairments. Pharmacological manipulation of specific neural circuits to optimize therapeutic index is an unrealized goal in neurology and psychiatry. AMPA receptors are important for excitatory synaptic transmission, and their antagonists are antiepileptic. Although efficacious, AMPA-receptor antagonists, including perampanel (Fycompa), the only approved antagonist for epilepsy, induce dizziness and motor impairment. We hypothesized that blockade of forebrain AMPA receptors without blocking cerebellar AMPA receptors would be antiepileptic and devoid of motor impairment. Taking advantage of an AMPA receptor auxiliary protein, TARP γ-8, which is selectively expressed in the forebrain and modulates the pharmacological properties of AMPA receptors, we discovered that LY3130481 selectively antagonized recombinant and native AMPA receptors containing γ-8, but not γ-2 (cerebellum) or other TARP members. Two amino acid residues unique to γ-8 determined this selectivity. We also observed antagonism of AMPA receptors expressed in hippocampal, but not cerebellar, tissue from a patient with epilepsy. Corresponding to this selective activity, LY3130481 prevented multiple seizure types in rats and mice and without motor side effects. These findings demonstrate the first rationally discovered molecule targeting specific neural circuitries for therapeutic advantage.
Two Targets Are Better Than One: A New Strategy to Increase the Specificity of Anti-Epileptic Drugs
Increasing the Specificity of Anti-Epileptic Drugs To identify such a compound, they set up a screen by: 1) expressing a calcium permeable AMPA receptor in a cell line together with γ-8, 2) applying glutamate and a blocker of receptor desensitization together with the test compound, and 3) monitoring receptor activity with a calcium sensitive dye. Compounds that inhibited the calcium response in this assay were then further tested on AMPA receptors alone or AMPA receptors in combination with γ-2 to identify compounds that only inhibited AMPA receptors in combination with γ-8. Using this calcium indicator-based screen, they identified LY3130481, a compound not related to any known category or class currently in clinical use, as a selective inhibitor of AMPA receptors that are associated with TARP γ-8.
Next, the authors furthered characterized LY3130481 in vitro using voltage clamp recordings in cell lines. They showed that it inhibited γ-8-associated AMPA receptors at much lower concentrations than other TARPS, that it inhibited all four of the AMPA receptor subunits, and that it functioned as a noncompetitive antagonist. They then moved on to recording AMPA receptor currents in mouse brain slices and in vivo, and showed that LY3130481 blocked evoked excitatory transmission in hippocampal slices from wildtype but not γ-8 knockout mice, and that it blocked neuronal activity induced by application of AMPA but not NMDA in anesthetized mice. To assess LY3130481's potential as an antiepileptic drug, they showed that it suppressed clonic convulsions induced by pentylenetrazole (PTZ) and that it was effective at suppressing convulsions in mice with kainate-induced epilepsy. Importantly, LY3130481 was effective at a concentration that caused low levels of motor deficits, which were assessed by a blinded investigator using a rating system that the authors developed to measure gait abnormalities, falling, and loss of righting. Perampanel and GYKI52466, another AMPA receptor antagonist, were also effective at suppressing convulsions, but only at doses that produced higher levels of motor impairment and decreases in locomotion.
Although neurotransmitter receptors and ion channels are attractive drug targets because they have a powerful influence on the activity of cells, many of them are expressed in a wide range of cell types in the brain. However, they are often bound to different auxiliary proteins, many of which show cell type-specific expression in the brain, which means that finding drugs that bind to a specific combination of two molecules should be a workable strategy to increase specificity. There are existing drugs that interact with auxiliary subunits of other ion chan nels, but these molecules were not discovered in targeted screens. Here, Kato et al. identified the compound LY3130481 as a selective inhibitor of γ-8-associated AMPA receptors, demonstrating that auxiliary proteins can be exploited to achieve a greater specificity in drug targeting. Although there are other, more specific approaches to targeting drugs in development (6) , many of these rely on genetically encoded expression of an intermediate molecule, an approach that is feasible in animal models but harder to implement in humans. Whether LY3130481-or any compound related to it-will ever be developed for the treatment of epilepsy is uncertain. However, this study at least provides proof of principle that strategies to develop pharmaceuticals that are more selective for specific brain regions, cell types, and circuits have the potential to vastly improve the treatment of epilepsy and other neurological diseases.
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